Androgen Therapy for Lower-Risk Myelodysplastic Syndrome
ConclusionOur data suggest that androgen can be a reasonable treatment option for lower-risk MDS patients with significant cytopenia. Prospective studies are warranted to investigate the efficacy of androgen therapy in lower-risk MDS.DisclosuresNo relevant conflicts of interest to declare.
Source: Blood - Category: Hematology Authors: Choi, E.-J., Lee, J.-H., Park, H.-S., Lee, J.-H., Seol, M., Lee, Y.-S., Kang, Y.-A., Jeon, M., Woo, J. M., Lee, K. H. Tags: 637. Myelodysplastic Syndromes-Clinical Studies: Poster I Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Aplastic Anemia | Hematology | Leukemia | Myelodysplastic Syndrome | Study | Thrombocytopenia